Ozempic, Mounjaro and Wegovy may not be the lightbulb, jet airplane or internet, but their impact is expected to be so significant it could shift GDP.

Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of the popular diabetes and obesity treatments continue to improve, federal regulators said Friday.

The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk’s popular weight-loss and diabetes drugs, Wegovy and Ozempic, a declaration that will curtail widespread sales of cheaper copies made by compounding pharmacies.